ABSTRACT
Gastrointestinal stromal tumor(GIST) ,a kind of rare tumor,takes 1%～3% of all tumors in digestive tract,but are the most common in mesenehymal neoplasm.At present,the primal treatment of GIST is surgical operation,standard and rationality of surgery is the significant fatter that affects its curative effect.While imatinib is the main therapeutic tool for GIST that can' t benn resected or recurrence after operation.There is no definite circumscription between optimum and malignancy,there are many factors that influence the prognosis of GIST.We commonly apply Fletcher grading to evaluate the risk of GIST.
ABSTRACT
Gastrointestinal stromal tumors are rare tumors of alimentary tract and originated from the interstitial Cajal cells,with acquired mutation of KIT(CD117).Surgery is the main therapy for resectable tumors,while imatinib,a small-molecule inhibitor of receptor of tyrosine kinase,plays an important role in treating metastatic and recurrent tumors.